Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients

Yuki Fujioka, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 192.

https://doi.org/10.1182/blood-2019-130300

Published: 2019

Journal Articles

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Takahiro Kobayashi, MD PhD, Yuki Fujioka, MD PhD, Sho Ikeda, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 1792.

https://doi.org/10.1182/blood-2019-125649

Published: 2019

Journal Articles

Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens

Yuki Fujioka, MD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD

Blood (2016) 128 (22): 4240.

https://doi.org/10.1182/blood.V128.22.4240.4240

Published: 2016

Journal Articles

Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes

Shuhei Kurosawa, Noriko Doki, Masahiro Suyama, Satoshi Sasajima, Aiko Igarashi, Iyo Mimura, Hidetoshi Morita, Yuki Fujioka, MD, Hiroyoshi Nishikawa, MD PhD, Yutaka Shimazu, Wataru Suda, Masahira Hattori, Yuho Najima, Kazuhiko Kakihana, Hisashi Sakamaki, Kenya Honda, Kazuteru Ohashi

Blood (2016) 128 (22): 4577.

https://doi.org/10.1182/blood.V128.22.4577.4577

Published: 2016

Journal Articles

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Shinsuke Noguchi, MD, Hiroyoshi Nishikawa, MD, PhD, Hirobumi Saitoh, MD, PhD, Atsushi Ohshima, MD, PhD, Kenichi Sawada, MD, PhD, Shimon Sakaguchi, MD PhD, Naoto Takahashi, MD PhD FJSIM

Blood (2015) 126 (23): 2219.

https://doi.org/10.1182/blood.V126.23.2219.2219

Published: 2015

NARROW

Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens

Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Email alerts

ASH Publications

American Society of Hematology

Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens

Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only